Fund research to find a cure for Fibrodysplasia Ossificans Progressiva while supporting, connecting, and advocating for individuals with FOP and their families, and raising awareness worldwide.
Key people
Jeannie L. Peeper, BA, Founder and President Emeritus Kristi Gonzales, Board Chairperson Megan Olsen, Vice-Chairperson Paul Brinkman, PhD, Secretary Gary McGuire, B.Comm., Treasurer
The International Fibrodysplasia Ossificans Progressiva Association (IFOPA) is a US-based 501(c)(3)non-profit organization supporting medical research, education and communication for those afflicted by the rare genetic condition Fibrodysplasia Ossificans Progressiva (FOP). IFOPA's mission is to fund research to find a cure for FOP while supporting, connecting, and advocating for individuals with FOP and their families, and raising awareness worldwide. IFOPA is governed by a volunteer board of directors which may range in number from 9 to 15, at least one of whom must have FOP. The association's location is 1520 Clay St., Suite H2, North Kansas City, MO, 64116, part of the Kansas City, Missouri metropolitan area.
IFOPA was founded in 1988 by Jeannie L. Peeper. Diagnosed with FOP in 1962 at age four, Peeper graduated from college in 1985 with a bachelor of arts degree in social work. Michael Zasloff, then at the National Institutes of Health (NIH), was studying FOP and put Peeper in contact with all FOP patients known to the NIH, eighteen in total, to whom Peeper mailed a questionnaire. Eleven responded. In early 1988, Peeper started a newsletter called FOP Connection in collaboration with Nancy Sando, one of the respondents. In June of that year, Peeper founded the IFOPA to facilitate fund raising for FOP research and generally create awareness of the disease. With an initial association membership of eleven, Peeper became the inaugural president and Sando was appointed vice president. In 1989, Peeper collaborated with the University of Pennsylvania to support establishment of the FOP Collaborative Research Project, and in 1992, the Center for Research in FOP and Related Disorders, efforts spearheaded by Drs. Frederick Kaplan, Michael Zasloff, and Eileen Shore.
Throughout the 1990s, IFOPA organized two international symposiums on FOP and several FOP family meetings. In the first decade of the 2000s, two more international symposiums were hosted by IFOPA, and other FOP scientific and family meetings were held in Argentina, Brazil, Canada, France, Germany, Italy, The Netherlands, Sweden, and the UK. In April 2006, the Center for Research in FOP discovered the FOP gene. By 2020, the organization had over 500 members from 57 countries and had partnered with FOP organizations and communities on all continents except Antarctica.
In 2010, IFOPA implemented the first annual Jeannie L Peeper Awards to recognize philanthropy, community involvement, international leadership and youth leadership in support of the FOP cause. Also in 2010, the Central Florida Chapter of the Association of Fund Raising Professionals named Peeper as winner of the 2010 Lifetime Achievement Award for her work in founding and establishing the IFOPA. A gathering of FOP families, supporters, researchers, and pharmaceutical industry representatives was held in Orlando in late 2013 on the 25th anniversary of the Association.
IFOPA hosted FOP drug development forums in 2014 and 2016 in Boston, 2017 in Sardinia Italy, and 2019 in Orlando. The forums brought together FOP experts to discuss the latest research, solve drug development challenges and strengthen the global network of research collaborations. The 2019 Drug Development Forum attracted 154 attendees from 19 countries including researchers, clinicians, biotech and pharmaceutical company representatives, regulators, advocates and people living with FOP.[1]
Quoting the 27th Annual Report of the FOP Collaborative Research Project "As of January 1, 2018, there were 37 research universities and/or clinical centers actively engaged in FOP research; 18 in the United States & Canada, 12 in Europe, five in Asia, one in Africa and one in Australia. As of January 1, 2018, there were 12 pharmaceutical and biotechnology companies actively developing drugs for FOP based on a multitude of hard targets, and over 30 companies that have expressed interest."[2]
In early 2017, IFOPA closed its Orlando office and moved administrative operations to North Kansas City, Missouri. A reorganization plan entailed creation of several new positions as follows: Director of Research Development and Partnerships, Family Services Manager, Donor Relations and Administrative Coordinator, Community Fundraising Manager, and FOP Registry Project Director.
Use of funds and fund raising
Historically, IFOPA has allocated over 80% of its annual budget to medical research and programs, donating in the range of $350,000 to $650,000 annually to the FOP Laboratory. IFOPA is a GuideStar Gold Participant by virtue of the public information IFOPA provides beyond that available from the IRS.[3] General overhead, defined as a combination of fund raising and management expenses, has for the past decade averaged below the Association of Fundraising Professionals statement that the average American believes 23 cents on the dollar being spent on such costs is a reasonable figure. IFOPA's financial statements and 990s are posted on the IFOPA website.
IFOPA fund raising results principally from family-organized activities rather than large nationwide events. In addition to the association's own annual appeal, several grants, and traditional family/friends letter drives, the range of family fund raisers includes golf tournaments, barbecues, bingos, auctions, comedy shows, rock concerts, holiday card sales, raffles, suppers, athletic events, and a variety of other social events and receptions. Some of the more unusual fund raisers include an annual Burns Supper in Aberdeen Scotland, an ice fishing contest, and the auctioning of a quilt decorated with a double helical border symbolizing both the DNA double helix and the quest to find a cure. In 2010, the association established the Jeannie Peeper Heritage Society, a fund raising program that targets major donors and estate giving.
Medical and scientific advisors
IFOPA's medical and scientific advisors are Frederick S. Kaplan, Eileen M. Shore, and Michael Zasloff. The foregoing advise the association on issues such as family support and counseling, dissemination of medical documents and treatment guidelines, medical document translation, physician awareness strategies, research funding requests and initiatives, and other matters for which their expertise is required.
Frederick S Kaplan Co-Director Center for Research in FOP.Eileen Shore Co-Director Center for Research in FOP
Kaplan is the Isaac and Rose Nassau Professor of Orthopaedic Molecular Medicine and Chief of the Division of Orthopaedic Molecular Medicine at the Perelman School of Medicine at the University of Pennsylvania. Kaplan co-directs the Center for Research in FOP and Related Disorders and is recognized as the world's leading expert on genetic disorders of heterotopic ossification and skeletal metamorphosis.[4] In 1997, Kaplan was awarded the first endowed chair in the USA for orthopaedic molecular medicine. In 2006, Newsweek named Kaplan as one of "15 people who make America great".[5] In 2009, Kaplan was elected to the Institute of Medicine, an organization established by the United States National Academy of Sciences to honor professional achievement in the health sciences.
Shore is the Cali and Weldon Research Professor in FOP, and Professor of Orthopaedic Surgery and Genetics in the Perelman School of Medicine at the University of Pennsylvania, Co-Director of the Center for Research in FOP and Related Disorders, and director of the FOP Molecular Biology Laboratory. She is a past-president of the Advances in Mineral Metabolism (AIMM) Board of Directors and served on the American Society of Bone and Mineral Research (ASBMR) Council. Shore was awarded a PhD from the University of Pennsylvania (Cell and Molecular Biology) followed by post-doctoral training in cell biology at the Fox Chase Cancer Center in Philadelphia. Shore's collaboration with Kaplan led to the discovery of the mutated genes in both FOP and POH Progressive osseous heteroplasia.[6][7]
Zasloff is Scientific Director, MedStar Georgetown Transplant Institute, Georgetown University School of Medicine. In the early 1980s, during his tenure at the National Institutes of Health as Chief of the Human Genetics Branch, he began clinical and basic studies of FOP and helped found the IFOPA with Jeannie Peeper. In 1989, as the Upham Professor of Pediatrics and Genetics at the University of Pennsylvania and Chief of the Division of Human Genetics of the Children's Hospital of Philadelphia, he began his collaboration with Fred Kaplan to find both the cause and cure of FOP.
Services and programs
As a result of the rareness of FOP, the condition is little known even among medical clinicians. Close to 90% of FOP patients worldwide are misdiagnosed.[8] In such circumstances, the association directly supports research, makes information about FOP including symptoms and treatment guidelines available to both physicians and families, and supports afflicted families with mentoring, family meetings and an information network. Below are IFOPA's programs of research, education, family support, and advocacy. Additional information about these programs, including downloadable reports, articles and other materials, may be obtained from the IFOPA website.
Research
The IFOPA provides pharmaceutical companies developing therapies for FOP with patient perspectives and input when needed and appropriate. Active clinical trials are posted at www.clinicaltrials.gov and can be found using the search term "fibrodysplasia." Also see the Drug Development tab on the IFOPA website.
In 2015, IFOPA initiated the Competitive Grant Program for research focused on new therapeutic approaches likely to have near-term clinical or translational relevance. One or several grants are awarded for a total of $100,000 annually, adjudication occurring by an independent Scientific Advisory Board. The program is funded by an anonymous family donor.
Provides and supports the FOP Connection Registry, a global voluntary secure multi-lingual web-based database to collect and report demographics, disease and quality-of-life information from FOP patients. Enables health care professionals, clinical researchers, and drug developers to better understand the clinical characteristics and disease progression in the larger population of FOP patients.
Administers scientific research studies on FOP members facing additional afflictions
Organizes the donation of fallen baby teeth of FOP patients for the FOP Lab. The teeth are used to harvest tissue progenitors, thereby enabling research on FOP cell differentiation.
Education
Provides education to the medical community about early symptoms of FOP.
Develops, publicizes and distributes videos, brochures and information about FOP and issues relating to those diagnosed with FOP via the IFOPA website and YouTube.
Provides FOP Facts in Brief: Contains brief facts on the following: What is FOP?; an example of the typical progression of FOP; demographics of FOP; clinical characteristics of FOP; finding a cure and treatment for FOP.
Family support
An association website that provides the public with information about FOP, developments in medical research, links to relevant websites, and contact information.
The Betty Ann Laue/IFOPA Resource Center: a central clearinghouse for information about FOP located at the IFOPA office in Florida.
The Medical Management of Fibrodysplasia Ossificans Progressiva: Current Treatment Considerations (March 2019).[9]
What is FOP? A Guidebook for Families and What is FOP? Questions and Answers for the Children are resource packages written for families dealing with FOP.
Medical Binder: each IFOPA member with FOP is provided with a binder that organizes and stores all information and medical documents needed by physicians in an emergency or for regular doctor appointments or hospital stays. The binder includes emergency contact numbers, current and past prescriptions, medical history, and medications and supplements.
FOPonline: an online member forum for discussion, support and research news.
LIFE Awards, "Living Independently with Full Equality" awards provide funding to enable independent living for those with FOP.
FOP Connection is the IFOPA's electronic quarterly newsletter. It features pictures and articles about and by members, fund raising events, donor acknowledgment, research developments, and suggestions and resources for living with FOP.
Mentoring Program provides a family-to-family connection with volunteer representatives in addition to staff support. Each volunteer is either personally afflicted with FOP or is the parent/sibling/caregiver of a person with FOP.
Symposia and meetings involving FOP patients with health practitioners who specialize in FOP in a collaborative forum to discuss FOP research, exchange information, and share coping strategies.
International President's Council: a world-wide network of volunteers who locate FOP families in their countries, establish local FOP organizations and share information regarding awareness activities, fund raising events and other FOP-related activities.
Translation Project: a service delivered largely by international volunteers (typically International President's Council representatives) who provide IFOPA documents and other materials in major languages (including at least French, German, Portuguese, Spanish, and Swedish).
Traveling Resource Center provides the global FOP community with information and instructions regarding tools and gadgets that help FOP patients to overcome their disabilities and live independently.
E-Learning Events - provides and shares information among members about overcoming common obstacles and everyday situations through video seminars and other web-enhanced communication methods.
PrayforFOPHealing is an online group that gives IFOPA members an opportunity to share prayer requests, inspirational quotes and poems and talk about how faith sustains them.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is one of the institutes and centers that make up the National Institutes of Health, an agency of the United States Department of Health and Human Services (HHS).
Fibrodysplasia ossificans progressiva, also called Münchmeyer disease or formerly myositis ossificans progressiva, is an extremely rare connective tissue disease in which fibrous connective tissue such as muscle, tendons, and ligaments turn into bone tissue. It is the only known medical condition where one organ system changes into another. It is a severe, disabling disorder with no cure or treatment.
The Perelman School of Medicine, commonly known as Penn Med, is the medical school of the University of Pennsylvania, a private research university in Philadelphia, Pennsylvania. Founded in 1765, the Perelman School of Medicine is the oldest medical school in the United States and one of the seven Ivy League medical schools.
Myositis ossificans comprises two syndromes characterized by heterotopic ossification (calcification) of muscle. The World Health Organization, 2020, has grouped myositis ossificans together with fibro-osseous pseudotumor of digits as a single specific entity in the category of fibroblastic and myofibroblastic tumors.
Heterotopic ossification (HO) is the process by which bone tissue forms outside of the skeleton in muscles and soft tissue.
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on transformative medicines in three therapeutic areas: oncology, rare disease and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Activin A receptor, type I (ACVR1) is a protein which in humans is encoded by the ACVR1 gene; also known as ALK-2. ACVR1 has been linked to the 2q23-24 region of the genome. This protein is important in the bone morphogenic protein (BMP) pathway which is responsible for the development and repair of the skeletal system. While knock-out models with this gene are in progress, the ACVR1 gene has been connected to fibrodysplasia ossificans progressiva, a very rare progressive genetic disease characterized by heterotopic ossification of muscles, tendons and ligaments. It is a bone morphogenetic protein receptor, type 1.
Bone disease refers to the medical conditions which affect the bone.
The American Society for Bone and Mineral Research (ASBMR) is a professional, scientific and medical society established in 1977 to promote excellence in bone and mineral research and to facilitate the translation of that research into clinical practice. The ASBMR has a membership of nearly 4,000 physicians, basic research scientists, and clinical investigators from around the world.
Harry Raymond Eastlack, Jr. was the subject of the most recognized case of FOP from the 20th century. His case is also particularly acknowledged, by scientists and researchers, for his contribution to medical advancement. After suffering from a rare, disabling, and currently incurable genetic disease, Eastlack decided to have his skeleton and medical history donated to the Mütter Museum of the College of Physicians of Philadelphia in support of FOP research. His skeleton is one of the few FOP-presenting, fully articulated ones in existence, and it has proved valuable to the study of the disease.
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Progressive osseous heteroplasia is a cutaneous condition characterized by cutaneous or subcutaneous ossification.
St. Francis Hospital is a general medical and surgical hospital located in Columbus, Georgia, United States, and is accredited by the Joint Commission.
Michael A. Zasloff is an American physician, medical researcher, and entrepreneur. Zasloff is primarily known for his work on antimicrobial peptides.
Palovarotene, sold under the brand name Sohonos, is a medication used for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. It is a highly selective retinoic acid receptor gamma (RARγ) agonist.
FOP Friends, formerly Friends of Oliver, is a registered charity in the United Kingdom established on 1 March 2012. It aims to raise funds that are needed to find effective treatments for the rare genetic condition fibrodysplasia ossificans progressiva (FOP). The charity also works to raise awareness and understanding of FOP amongst medical communities and the general public.
The 21st Century Cures Act is a United States law enacted by the 114th United States Congress in December 2016 and then signed into law on December 13, 2016. It authorized $6.3 billion in funding, mostly for the National Institutes of Health. The act was supported especially by large pharmaceutical manufacturers and was opposed especially by some consumer organizations.
Frederick S. Kaplan is an American medical doctor specializing in research of musculoskeletal disorders such as fibrodysplasia ossificans progressiva (FOP).
Eileen M. Shore is an American medical researcher and geneticist specializing in research of muscoskeletal disorders such as fibrodysplasia ossificans progressiva.
Carol Orzel was an American woman with fibrodysplasia ossificans progressiva (FOP). She advocated for research into FOP and was an activist for disability rights. Before her death, she requested that her skeleton be displayed in the Mütter Museum.
↑ Shore, Eileen M.; Xu, Meiqi; Feldman, George J.; Fenstermacher, David A.; Cho, Tae-Joon; Choi, In Ho; Connor, J Michael; Delai, Patricia; Glaser, David L.; Lemerrer, Martine; Morhart, Rolf; Rogers, John G.; Smith, Roger; Triffitt, James T.; Urtizberea, J Andoni; Zasloff, Michael; Brown, Matthew A.; Kaplan, Frederick S. (2006). "A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva". Nature Genetics. Nature.com. 38 (5): 525–527. doi:10.1038/ng1783. PMID16642017. S2CID41579747.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
